Every day, cancer claims nearly 2,000 lives in the U.S. alone. Many cancers are detected too late, when treatments are less likely to succeed.
Finding cancer early can make a world of difference in outcomes and survival. For example, when colon cancer is found before it spreads, the 5-year survival rate is more than 6x higher.1
The Vallania Study is part of our multi-cancer research program focused on developing next-generation blood tests to detect cancer in its earliest, most treatable stages.
The Vallania Study is enrolling about 5,400 individuals aged 30 and above who are willing to provide a blood sample. The study aims to develop blood tests that can provide accurate, convenient and patient-friendly options for cancer screening.
Freenome’s clinical studies are named for employees’ loved ones who have battled cancer. This study honors a Freenome scientist’s mother who battled pancreatic cancer.
Our study is looking for people who have been diagnosed with cancer and have not yet received treatment.
We are also looking for participants who do not have signs or symptoms of cancer, or a known cancer diagnosis.
For more information: www.clinicaltrials.gov
Those who participate in the non-cancer group will receive a follow up via phone or medical records review one year after blood draw.
Freenome, a biotechnology company, has pioneered a comprehensive platform for early cancer detection using a routine blood draw. The company combines its expertise in molecular biology with advanced computational biology and machine learning to recognize disease-associated patterns among billions of biomarkers.
Privacy policy
© 2023 Freenome Holdings, Inc.
FREENOME is a registered trademark of Freenome Holdings, Inc. All rights reserved.